BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bayat M, Asemani Y, Mohammadi MR, Sanaei M, Namvarpour M, Eftekhari R. An overview of some potential immunotherapeutic options against COVID-19. Int Immunopharmacol 2021;95:107516. [PMID: 33765610 DOI: 10.1016/j.intimp.2021.107516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Omotuyi O, Olubiyi O, Nash O, Afolabi E, Oyinloye B, Fatumo S, Femi-oyewo M, Bogoro S. SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody. Computers in Biology and Medicine 2022;142:105226. [DOI: 10.1016/j.compbiomed.2022.105226] [Reference Citation Analysis]
2 Bayat M, Asemani Y, Najafi S. Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. Int Immunopharmacol 2021;97:107679. [PMID: 33930707 DOI: 10.1016/j.intimp.2021.107679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Salinas F, Marelli BE, Sanguineti S, Goldbaum F, Muñoz L, Etchevers L, Silvestrini P, Notaro US, Salvetti NR, Zylberman V, Ortega HH. Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies. Toxicol Appl Pharmacol 2022;434:115796. [PMID: 34785274 DOI: 10.1016/j.taap.2021.115796] [Reference Citation Analysis]
4 Zhang J, Zhang H, Sun L. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? mAbs 2022;14:2031483. [DOI: 10.1080/19420862.2022.2031483] [Reference Citation Analysis]